FDA skeptical of benefits from experimental ALS drug
WASHINGTON — Federal health regulators issued a negative review Monday of a closely watched experimental drug for the debilitating illness known as Lou Gehrig’s disease, after months of lobbying by patient advocates urging approval.
The drug from Amylyx Pharmaceuticals has become a rallying cause for patients with the deadly neurodegenerative disease ALS, their families and members of Congress who’ve joined in pushing the Food and Drug Administration to greenlight the drug.
ADVERTISING
But regulators said in a review that the company’s small study was “not persuasive,” due to missing data, errors in enrolling patients and other problems.
On Wednesday, a panel of FDA advisers will take a non-binding vote on whether the drug should be approved.
The meeting is being closely watched as an indicator of the FDA’s approach to experimental drugs with imperfect data and its ability to withstand outside pressure.
The FDA’s negative stance on the drug sets up a tense scenario at Wednesday’s public session, where several dozen ALS patients and advocates are scheduled to speak.
The agency will consider the input from its advisory panel before making a final decision on the drug, expected by June.
ALS, or amyotrophic lateral sclerosis, destroys nerve cells needed to walk, talk, swallow and — eventually — breathe. There is no cure and most people die within three to five years.
Amylyx’s drug is a combination of two older drugs: a prescription medication for liver disorders and a dietary supplement associated with traditional Chinese medicine.
Amylyx has patented the combination in a powder and says the chemicals help protect cells from early death.
